Sphingosine‐1‐phosphate (S1P) receptors: Promising drug targets for treating bone‐related diseases. Issue 8 (10th March 2020)

• Record Type: Journal Article
• Authors: Zhang, Lincheng; Dong, Yutong; Wang, Yiran; Hu, Wenhui; Dong, Shiwu; Chen, Yueqi
• Is Part Of: Journal of cellular and molecular medicine. Volume 24:Issue 8(2020)
• Page Start: 4389
• Page End: 4401
• Publication Date: 2020-03-10
• Subjects: cancer‐related bone metastasis -- inflammatory osteolysis -- osteoporosis -- S1P receptors; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.15155
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Sphingosine‐1‐phosphate (S1P) is a natural bioactive lipid molecule and a common first or second messenger in the cardiovascular and immune systems. By binding with its receptors, S1P can serve as mediator of signalling during cell migration, differentiation, proliferation and apoptosis. Although the predominant role of S1P in bone regeneration has been noted in many studies, this role is not as well‐known as its roles in the cardiovascular and immune systems. In this review, we summarize previous research on the role of S1P receptors (S1PRs) in osteoblasts and osteoclasts. In addition, S1P is regarded as a bridge between bone resorption and formation, which brings hope to patients with bone‐related diseases. Finally, we discuss S1P and its receptors as therapeutic targets for treating osteoporosis, inflammatory osteolysis and bone metastasis based on the biological effects of S1P in osteoclastic/osteoblastic cells, immune cells and tumour cells.